Cephalalgia

Article	Citations
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution	155
Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults	108
Erenumab versus topiramate for the prevention of migraine – a randomised, double-blind, active-controlled phase 4 trial	77
Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia	70
Isolated intracranial hypertension associated with COVID-19	67
A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention	66
Migraine therapeutics differentially modulate the CGRP pathway	59
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study	59
Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine	58
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study	57
Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients	54
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients	54
The migraineur’s brain networks: Continuous resting state fMRI over 30 days	53
Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis	53
The presence of headache at onset in SARS-CoV-2 infection is associated with long-term post-COVID headache and fatigue: A case-control study	52
Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache	45
Characteristics of headache attributed to COVID-19 infection and predictors of its frequency and intensity: A cross sectional study	44
I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children	43
Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study	43
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study	40
Clinical, oculographic, and vestibular test characteristics of vestibular migraine	40
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database	38
Daily persistent headache after a viral illness during a worldwide pandemic may not be a new occurrence: Lessons from the 1890 Russian/Asiatic flu	38
Prevalence of neck pain in migraine: A systematic review and meta-analysis	37
CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis	37

Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study	36
Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study	36
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis	34
Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study	34
Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study	34
E-diary use in clinical headache practice: A prospective observational study	31
ATP sensitive potassium (KATP) channel inhibition: A promising new drug target for migraine	30
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials	30
Sex differences in prevalence of migraine trigger factors: A cross-sectional study	30
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial	30
Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial	30
Incidence of spontaneous intracranial hypotension in a community: Beverly Hills, California, 2006–2020	29
Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts	29
Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers	29
A systematic review of treatment for patients with burning mouth syndrome	28
No efficacy of transcranial direct current stimulation on chronic migraine with medication overuse: A double blind, randomised clinical trial	28
The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic	27
CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine	27
Salivary CGRP can monitor the different migraine phases: CGRP (in)dependent attacks	26
Cluster headache in Asian populations: Similarities, disparities, and a narrative review of the mechanisms of the chronic subtype	26
The role of cytokines in migraine: A systematic review	26
Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients	26
Non-invasive vagus nerve stimulation for primary headache: A clinical update	26
COVID-19-related headache and sinonasal inflammation: A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection	25
Diagnosis and treatment of idiopathic intracranial hypertension	25
Two hundred and forty-eight cases of visual snow: A review of potential inciting events and contributing comorbidities	25
Concomitant continuous pain in patients with trigeminal neuralgia is associated with trigeminal nerve root atrophy	24
Evidence of localized and widespread pressure pain hypersensitivity in patients with tension-type headache: A systematic review and meta-analysis	24
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label ext	24
Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura	24
Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society	23
Interictal amylin levels in chronic migraine patients: A case-control study	23
Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review	22
Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system	22
Opening of BKCa channels alters cerebral hemodynamic and causes headache in healthy volunteers	22
Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache	22
The migraine postdrome: Spontaneous and triggered phenotypes	21
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain	21
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache	21
Hypersensitivity to calcitonin gene-related peptide in chronic migraine	21
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial	20
Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons	20
Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods	20
Oxytocin as a regulatory neuropeptide in the trigeminovascular system: Localization, expression and function of oxytocin and oxytocin receptors	20
Photophobia in migraine: A symptom cluster?	19
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine	19
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II	19
CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache	19
Validation of diagnostic ICHD-3 criteria for menstrual migraine	18
Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study	18

Effect of KATP channel blocker glibenclamide on levcromakalim-induced headache	18
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine	18
Post-traumatic headache due to mild traumatic brain injury: Current knowledge and future directions	18
Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients	18
Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study	18
Mechanical punctate pain threshold is associated with headache frequency and phase in patients with migraine	17
Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients	17
Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19	17
Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review	17
The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany	17
Prevalence of pre-cluster symptoms in episodic cluster headache: Is it possible to predict an upcoming bout?	17
Migraine and aura triggered by normobaric hypoxia	17
Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report	17
Baseline tear fluid CGRP is elevated in active cluster headache patients as long as they have not taken attack abortive medication	16
Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study	16
Combination of acupuncture and medical training therapy on tension type headache: Results of a randomised controlled pilot study	16
Prevalence and characteristics of Alice in Wonderland Syndrome in adult migraineurs: Perspectives from a tertiary referral headache unit	16
Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks	16
Prevalence and risk factors of migraine and non-migraine headache in older people – results of the Heinz Nixdorf Recall study	16
Real-life treatment of cluster headache in a tertiary headache center – results from the Danish Cluster Headache Survey	16
How does the brain change in chronic migraine? Developing disease biomarkers	16
CGRP measurements in human plasma – a methodological study	16
Migraine presenting as isolated facial pain: A prospective clinical analysis of 58 cases	16
Vascular actions of peripheral CGRP in migraine-like photophobia in mice	15
Nocebo response in human models of migraine: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled, two-way crossover trials in migraine without aura and healthy volunt	15
[123I]-IMP single-photon emission computed tomography imaging in visual snow syndrome: A case series	15
The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache	15
Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications	15
Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial	15
High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients	15
Functional magnetic resonance imaging in migraine: A systematic review	15
Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine	15
The prevalence of headache disorders in children and adolescents in Iran: a schools-based study	15
Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury	14
Atrial fibrillation and migraine with aura in young adults with ischemic stroke	14
Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study	14
Comparing prospective headache diary and retrospective four-week headache questionnaire over 20 weeks: Secondary data analysis from a randomized controlled trial	14
Neurophysiological and biomolecular effects of erenumab in chronic migraine: An open label study	14
No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine	14
Clinical correlates of hypothalamic functional changes in migraine patients	14
Distinguishing persistent post-traumatic headache from migraine: Classification based on clinical symptoms and brain structural MRI data	14
Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-ana	14
Proposed modified diagnostic criteria for recurrent painful ophthalmoplegic neuropathy: Five case reports and literature review	14
A prolactin-dependent sexually dimorphic mechanism of migraine chronification	14
Neurovascular contact plays no role in trigeminal neuralgia secondary to multiple sclerosis	13
Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data	13
Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic	13
Adverse effects of erenumab on cerebral proliferative angiopathy: A case report	13
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis	13
The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice	13
Pediatric-onset trigeminal autonomic cephalalgias: A systematic review and meta-analysis	13
Muscle endurance training of the neck triggers migraine attacks	13
No structural brain alterations in new daily persistent headache – a cross sectional VBM/SBM study	12
New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy	12
Photophobia and allodynia in persistent post-traumatic headache are associated with higher disease burden	12
Identification of work accommodations and interventions associated with work productivity in adults with migraine: A scoping review	12
Intravenous lacosamide and phenytoin for the treatment of acute exacerbations of trigeminal neuralgia: A retrospective analysis of 144 cases	12
Melanopsin hypersensitivity dominates interictal photophobia in migraine	12
Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)	12
Time to retire ‘New daily persistent headache’: Mode of onset of chronic migraine and tension-type headache	12
The time sequence of brain MRI findings in spontaneous intracranial hypotension	12
Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports	12
Atogepant – an orally-administered CGRP antagonist – attenuates activation of meningeal nociceptors by CSD	12
A national Swedish case-control study investigating incidence and factors associated with idiopathic intracranial hypertension	12
The ICHD definition of ‘facial pain’ should be revised	12
Additional effects of pain neuroscience education combined with physiotherapy on the headache frequency of adult patients with migraine: A randomized controlled trial	12
TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine	12
Smooth muscle ATP-sensitive potassium channels mediate migraine-relevant hypersensitivity in mouse models	11
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine	11
Update in the understanding of new daily persistent headache	11
Developing an artificial intelligence-based headache diagnostic model and its utility for non-specialists’ diagnostic accuracy	11
Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature	11
Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention	11
Effect of Altmetric score on manuscript citations: A randomized-controlled trial	11
The migraine landscape on YouTube: A review of YouTube as a source of information on migraine	11
Poor social support and loneliness in chronic headache: Prevalence and effect modifiers	11
Determination of psychosocial factors in cluster headache – construction and psychometric properties of the Cluster Headache Scales (CHS)	11
Calcitonin receptor antibody validation and expression in the rodent brain	10
Reason to doubt the ICHD-3 7-day inclusion criterion for mild TBI-related posttraumatic headache: A nested cohort study	10
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial	10

The potential danger of blocking CGRP for treating migraine in CADASIL patients	10
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response	10
Efficacy of erenumab in chronic migraine patients with and without ictal allodynia	10
Migraine genetics: Status and road forward	10
Effectiveness of physiotherapy interventions on headache intensity, frequency, duration and quality of life of patients with tension-type headache. A systematic review and network meta-analysis	10
A systematic evaluation of primary headache management apps leveraging behavior change techniques	10
Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study	10
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study	10
A population-based survey for disabling headaches in Greece: Prevalence, burden and treatment preferences	10
Increased severity of closed head injury or repetitive subconcussive head impacts enhances post-traumatic headache-like behaviors in a rat model	10
Occipital ischaemic stroke after visual snow phenomenon – a case report	10
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2	10